What discharge medication regimen should be prescribed for a patient with lower right extremity deep vein thrombosis, a history of pulmonary embolism, anemia (hemoglobin ~8 g/dL), Lovenox held for an upcoming endoscopy, and a mixed metabolic acidosis/respiratory alkalosis?

Discharge Anticoagulation for DVT/PE with History of Recurrent VTE

This patient should be discharged on a direct oral anticoagulant (DOAC)—specifically apixaban, rivaroxaban, dabigatran, or edoxaban—rather than continuing Lovenox, with indefinite anticoagulation given the recurrent unprovoked VTE history. 1

Primary Anticoagulation Choice

The 2020 ASH guidelines provide a conditional recommendation for DOACs over vitamin K antagonists (VKAs) for treatment-phase therapy in acute VTE, based on moderate certainty evidence 1. The 2021 CHEST guidelines strengthen this to a strong recommendation for DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) over VKA for treatment-phase anticoagulation 2.

Why DOACs Over Lovenox Long-Term:

• Lower bleeding risk compared to warfarin 3
• No need for monitoring (critical given this patient's complex metabolic issues)
• Proven efficacy equivalent to LMWH/warfarin for VTE treatment 4
• Easier outpatient management for chronic therapy

Specific DOAC Selection:

Apixaban or rivaroxaban are preferred because:

• No lead-in parenteral anticoagulation required (unlike dabigatran/edoxaban)
• Patient already received Lovenox bridging during hospitalization
• Can start immediately at discharge

Dosing:

• Apixaban: 10 mg PO BID × 7 days, then 5 mg PO BID
• Rivaroxaban: 15 mg PO BID × 21 days, then 20 mg PO daily

Duration: Indefinite Anticoagulation Required

This patient requires indefinite anticoagulation based on:

• Recurrent VTE (history of PE + current chronic right lower extremity DVT) 1
• Unprovoked nature (no clear reversible trigger documented)

The ASH guidelines provide a strong recommendation for indefinite anticoagulation in patients with recurrent unprovoked VTE 1. This is non-negotiable given the high recurrence risk.

Critical Considerations for This Patient

Anemia (Hemoglobin 7.7-8.4 g/dL):

The anemia is NOT a contraindication to therapeutic anticoagulation but requires:

• Identify and address bleeding source (EGD was performed—results needed)
• Transfusion threshold: Maintain Hgb >7-8 g/dL while on anticoagulation
• Recent evidence shows anemia in VTE patients increases long-term mortality but is not independently associated with major bleeding 5
• Monitor closely for 48-72 hours post-discharge if possible

Thrombocytopenia (Platelets 72-83):

Mild thrombocytopenia is NOT an absolute contraindication to anticoagulation:

• Platelet count >50,000 generally allows therapeutic anticoagulation
• Monitor for HIT (heparin-induced thrombocytopenia) given Lovenox exposure
• If platelets drop further <50,000, reassess risk/benefit

Metabolic Acidosis/Alkalosis:

This mixed disorder does NOT affect DOAC choice, but:

• Avoid dabigatran if significant renal dysfunction develops (current eGFR 97 is acceptable)
• The bicarbonate of 17 is improving and managed conservatively per nephrology

Liver Disease Considerations:

Respiratory alkalosis suggests underlying liver disease/hyperammonemia:

• Avoid DOACs if moderate-to-severe liver disease (Child-Pugh B or C) 1
• If significant hepatic dysfunction present, continue LMWH (Lovenox) instead
• Need liver function tests and coagulation parameters (INR) to assess severity
• If INR >1.5 or bilirubin significantly elevated, Lovenox 1 mg/kg SC q12h is safer than DOAC

Complete Discharge Medication Regimen

Anticoagulation (Primary):

IF liver function adequate (INR <1.5, no cirrhosis):

• Apixaban 10 mg PO BID × 7 days, then 5 mg PO BID indefinitely (preferred)
  • OR Rivaroxaban 15 mg PO BID × 21 days with food, then 20 mg PO daily with food indefinitely

IF moderate-to-severe liver disease present:

• Enoxaparin (Lovenox) 1 mg/kg SC q12h indefinitely 4

Supportive Medications:

For anemia:

• Iron supplementation (ferrous sulfate 325 mg PO TID) if iron deficiency confirmed
• Erythropoiesis-stimulating agent consideration if chronic kidney disease develops
• PPI continuation if upper GI bleeding source identified

For metabolic acidosis:

• Continue lactulose as prescribed (likely for hepatic encephalopathy)
• No sodium bicarbonate per nephrology recommendation
• Electrolyte repletion: Potassium supplementation PRN (currently 3.3-3.6)

For hyperglycemia:

• Glucose monitoring (consistently 115-168 mg/dL)
• Consider metformin or other oral agent if not contraindicated by renal/liver function
• Diabetes education and outpatient endocrine follow-up

Common Pitfalls to Avoid

1. Do NOT use aspirin alone for extended VTE prophylaxis in this patient—inadequate for recurrent VTE 1
2. Do NOT use reduced-dose DOAC initially—this is only for extended prophylaxis after completing full-dose treatment phase
3. Do NOT discharge on Lovenox long-term unless liver disease contraindicates DOAC—patient compliance and cost are prohibitive
4. Do NOT stop anticoagulation at 3 or 6 months—recurrent unprovoked VTE mandates indefinite therapy
5. Ensure patient can afford DOAC—if cost-prohibitive, warfarin with INR monitoring is acceptable alternative (target INR 2.0-3.0) 1

Follow-Up Requirements

• 48-72 hours: Recheck CBC to ensure hemoglobin stable on anticoagulation
• 2 weeks: Assess for bleeding complications, medication adherence
• 3 months: Reassess need for continued anticoagulation (will be indefinite)
• Ongoing: Annual bleeding risk assessment, but continue anticoagulation unless major bleeding occurs